Pasithea Therapeutics (KTTA) Equity Average (2021 - 2024)
Historic Equity Average for Pasithea Therapeutics (KTTA) over the last 4 years, with Q3 2024 value amounting to $17.0 million.
- Pasithea Therapeutics' Equity Average fell 4686.26% to $17.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $17.0 million, marking a year-over-year decrease of 4686.26%. This contributed to the annual value of $32.9 million for FY2023, which is 2983.65% down from last year.
- Latest data reveals that Pasithea Therapeutics reported Equity Average of $17.0 million as of Q3 2024, which was down 4686.26% from $18.0 million recorded in Q2 2024.
- In the past 5 years, Pasithea Therapeutics' Equity Average registered a high of $50.7 million during Q2 2022, and its lowest value of $17.0 million during Q3 2024.
- Its 4-year average for Equity Average is $35.2 million, with a median of $35.7 million in 2021.
- Per our database at Business Quant, Pasithea Therapeutics' Equity Average surged by 3150.64% in 2022 and then tumbled by 5174.5% in 2024.
- Quarter analysis of 4 years shows Pasithea Therapeutics' Equity Average stood at $33.9 million in 2021, then soared by 31.51% to $44.6 million in 2022, then plummeted by 42.02% to $25.9 million in 2023, then plummeted by 34.35% to $17.0 million in 2024.
- Its last three reported values are $17.0 million in Q3 2024, $18.0 million for Q2 2024, and $21.6 million during Q1 2024.